Reportlinker Adds Travel Vaccines Market to 2017 - Growth in International Travel and Higher Incidences of Infectious Diseases in Emerging Economies to Drive the Market
Apr 14, 2011, 07:01 ET
NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Travel Vaccines Market to 2017 - Growth in International Travel and Higher Incidences of Infectious Diseases in Emerging Economies to Drive the Market
Summary
GBI Research, the leading business intelligence provider, has released its latest research, "Travel Vaccines Market to 2017 – Growth in International Travel and Higher Incidences of Infectious Diseases in Emerging Economies to Drive the Market", which provides insights into the global travel vaccines market and market forecasts until 2017. The report provides an in-depth analysis of the top seven therapeutic indications for which travel vaccines are often prescribed, which includes hepatitis A, hepatitis B, rabies, typhoid fever, yellow fever, Japanese encephalitis and meningococcal meningitis. In addition, the report also includes insights into the travel vaccines R&D pipeline.
Scope
The scope of this report includes -
- Data and analysis on the global travel vaccines market.
- Annualized market data for the travel vaccines market from 2002 to 2010, with forecasts to 2017 for top seven geographies which includes the US, the UK, France, Germany, Italy, Spain and Japan.
- Market data on the therapeutic landscape which covers hepatitis A, hepatitis B, rabies, typhoid fever, yellow fever, Japanese encephalitis and meningococcal meningitis, including market size, market share and cost of vaccination.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the global travel vaccine market, which includes companies such as Sanofi-Pasteur, GlaxoSmithKline, Merck, Novartis and Intercell.
- Key M&A activities and Licensing Agreements that took place from 2005 to 2011 in the global travel vaccines market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth.
- Devise a more tailored country strategy through the understanding of key drivers and barriers of the region's antibacterial market.
- Develop key strategic initiatives by understanding the key focus areas and top selling antibacterial molecules of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 8
2 Global Travel Vaccines Market to 2017– Introduction 10
2.1 GBI Research Report Guidance 11
3 Global Travel Vaccines Market to 2017 – Market Overview 12
3.1 Introduction 12
3.2 Revenue Forecasts for the Travel Vaccines Market 12
3.3 Drivers and Barriers for the Travel Vaccines Market 13
3.3.1 Drivers for the Travel Vaccines Market 13
3.3.2 Barriers for the Travel Vaccines Market 14
4 Global Travel Vaccines Market to 2017 – Geographical Landscape 15
4.1 Revenue Analysis by Geography 15
4.1.1 The US 17
4.1.2 Top Five Countries of Europe 20
4.1.3 Japan 23
4.1.4 Rest of the World 26
5 Global Travel Vaccines Market to 2017 – Therapeutic Landscape 29
5.1 Hepatitis A 29
5.1.1 Introduction 29
5.1.2 Revenue 30
5.1.3 Cost of Vaccination 31
5.1.4 Vaccination Coverage 32
5.1.5 Drivers and Barriers for the Hepatitis A Market 33
5.2 Hepatitis B 34
5.2.1 Introduction 34
5.2.2 Revenue 35
5.2.3 Cost of Vaccination 36
5.2.4 Vaccination Coverage 37
5.2.5 Drivers and Barriers for the Hepatitis B Market 38
5.3 Rabies 39
5.3.1 Introduction 39
5.3.2 Revenue 40
5.3.3 Cost of Vaccination 41
5.3.4 Vaccination Coverage 42
5.3.5 Drivers and Barriers for the Rabies Market 43
5.4 Typhoid Fever 44
5.4.1 Introduction 44
5.4.2 Revenue 45
5.4.3 Cost of Vaccination 46
5.4.4 Vaccination Coverage 47
5.4.5 Drivers and Barriers for the Typhoid Fever Market 48
5.5 Yellow Fever 49
5.5.1 Introduction 49
5.5.2 Revenue 50
5.5.3 Cost of Vaccination 51
5.5.4 Vaccination Coverage 52
5.5.5 Drivers and Barriers for the Yellow Fever Market 53
5.6 Japanese Encephalitis 54
5.6.1 Introduction 54
5.6.2 Revenue 55
5.6.3 Cost of Vaccination 56
5.6.4 Vaccination Coverage 57
5.6.5 Drivers and Barriers for the Japanese Encephalitis Market 58
5.7 Meningococcal Meningitis 59
5.7.1 Introduction 59
5.7.2 Revenue 60
5.7.3 Cost of Vaccination 61
5.7.4 Vaccination Coverage 62
5.7.5 Drivers and Barriers for the Meningococcal Meningitis Market 63
5.8 Enterotoxigenic Escherichia Coli (Traveler's Diarrhea) 64
5.8.1 Introduction 64
5.8.2 Drivers and Barriers for the Enterotoxigenic Escherichia Coli Market 65
6 Travel Vaccines Market – Product Pipeline Analysis 66
6.1 Introduction 66
6.1.1 Research and Development Pipeline – Hepatitis A Vaccines 68
6.1.2 Research and Development Pipeline – Hepatitis B Vaccines 69
6.1.3 Research and Development Pipeline – Rabies Vaccines 74
6.1.4 Research and Development Pipeline – Typhoid Fever Vaccines 76
6.1.5 Research and Development Pipeline – Yellow Fever Vaccines 78
6.1.6 Research and Development Pipeline – Japanese Encephalitis Vaccines 79
6.1.7 Research and Development Pipeline – Enterotoxigenic Escherichia Coli Vaccines 80
6.1.8 Research and Development Pipeline – Meningococcal Meningitis Vaccines 81
7 Travel Vaccines Market – Competitive Landscape 84
7.1 Market Share Analysis: Travel Vaccines Market 84
7.2 Competitive Profiling 85
7.2.1 Sanofi Pasteur 85
7.2.2 GlaxoSmithKline plc 87
7.2.3 Merck & Co., Inc 88
7.2.4 Novartis AG 90
7.2.5 Intercell AG 91
8 Travel Vaccines Market – M&A Landscape 92
8.1 M&A Landscape 92
8.1.1 M&A Deals by Year 92
8.1.2 M&A Deals by Geography 93
8.1.3 M&A Deals by Value 94
8.1.4 Major M&A Deals by Value 95
8.1.5 M&A Deals by Deal Type 96
8.1.6 M&A Deals by Deal Sub-Type 97
8.2 R&D Licensing Agreements 98
8.2.1 Deals by Year 98
8.2.2 Deals by Geography 99
8.2.3 Deals by Value ($) 100
8.3 Co-Developments 101
8.3.1 Co-Developments by Year 101
8.3.2 Co-developments by Geography 102
9 Travel Vaccines Market – Appendix 103
9.1 Market Definitions 103
9.2 Abbreviations 103
9.3 Research Methodology 103
9.3.1 Coverage 103
9.3.2 Secondary Research 104
9.3.3 Primary Research 104
9.3.4 Expert Panel Validation 104
9.4 Contact Us 105
9.5 Disclaimer 105
9.6 Sources 105
1.1 List of Tables
Table 1: Travel Vaccines Therapeutics Market, Global, Revenue ($m), 2002-2010 12
Table 2: Travel Vaccines Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 12
Table 3: Travel Vaccines Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 15
Table 4: Travel Vaccines Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 16
Table 5: Travel Vaccines Therapeutics Market, the US, Revenue ($m), 2002-2010 17
Table 6: Travel Vaccines Therapeutics Market, the US, Revenue Forecasts ($m), 2010-2017 17
Table 7: Travel Vaccines Therapeutics Market, the US, Cost of Vaccination ($), 2002-2010 18
Table 8: Travel Vaccines Therapeutics Market, the US, Cost of Vaccination ($), 2010-2017 18
Table 9: Travel Vaccines Therapeutics Market, the US, Vaccinated Travelers (million), 2002-2010 19
Table 10: Travel Vaccines Therapeutics Market, the US, Vaccinated Travelers Forecasts (million), 2010-2017 19
Table 11: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2002- 2010 20
Table 12: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010- 2017 20
Table 13: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Cost of Vaccination ($), 2002-2010 21
Table 14: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Cost of Vaccination ($), 2010-2017 21
Table 15: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Vaccinated Travelers (million), 2002-2010 22
Table 16: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Vaccinated Travelers Forecasts (million), 2010-2017 22
Table 17: Travel Vaccines Therapeutics Market, Japan, Revenue ($m), 2002- 2010 23
Table 18: Travel Vaccines Therapeutics Market, Japan, Revenue Forecasts ($m), 2010-2017 23
Table 19: Travel Vaccines Therapeutics Market, Japan, Cost of Vaccination ($), 2002-2010 24
Table 20: Travel Vaccines Therapeutics Market, Japan, Cost of Vaccination ($), 2010-2017 24
Table 21: Travel Vaccines Therapeutics Market, Japan, Vaccinated Travelers (million), 2002-2010 25
Table 22: Travel Vaccines Therapeutics Market, Japan, Vaccinated Travelers Forecasts (million), 2010-2017 25
Table 23: Travel Vaccines Therapeutics Market, Rest of the World, Revenue ($m), 2002-2010 26
Table 24: Travel Vaccines Therapeutics Market, Rest of the World, Revenue Forecasts ($m), 2010-2017 26
Table 25: Travel Vaccines Therapeutics Market, Rest of the World, Cost of Vaccination ($), 2002-2010 27
Table 26: Travel Vaccines Therapeutics Market, Rest of the World, Cost of Vaccination ($), 2010-2017 27
Table 27: Travel Vaccines Therapeutics Market, Rest of the World, Vaccinated Travelers (million), 2002-2010 28
Table 28: Travel Vaccines Therapeutics Market, Rest of the World, Vaccinated Travelers Forecasts (million), 2010-2017 28
Table 29: Hepatitis A Therapeutics Market, Global, Revenue ($m), 2002-2010 30
Table 30: Hepatitis A Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 30
Table 31: Hepatitis A Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 31
Table 32: Hepatitis A Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 31
Table 33: Hepatitis A Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 32
Table 34: Hepatitis A Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 32
Table 35: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2002-2010 35
Table 36: Hepatitis B Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 35
Table 37: Hepatitis B Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 36
Table 38: Hepatitis B Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 36
Table 39: Hepatitis B Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 37
Table 40: Hepatitis B Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 37
Table 41: Rabies Therapeutics Market, Global, Revenue ($m), 2002-2010 40
Table 42: Rabies Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 40
Table 43: Rabies Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 41
Table 44: Rabies Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 41
Table 45: Rabies Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 42
Table 46: Rabies Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 42
Table 47: Typhoid Fever Therapeutics Market, Global, Revenue ($m), 2002-2010 45
Table 48: Typhoid Fever Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 45
Table 49: Typhoid Fever Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 46
Table 50: Typhoid Fever Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 46
Table 51: Typhoid Fever Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 47
Table 52: Typhoid Fever Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 47
Table 53: Yellow Fever Therapeutics Market, Global, Revenue ($m), 2002-2010 50
Table 54: Yellow Fever Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 50
Table 55: Yellow Fever Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 51
Table 56: Yellow Fever Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 51
Table 57: Yellow Fever Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 52
Table 58: Yellow Fever Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 52
Table 59: Japanese Encephalitis Therapeutics Market, Global, Revenue ($m), 2002-2010 55
Table 60: Japanese Encephalitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 55
Table 61: Japanese Encephalitis Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 56
Table 62: Japanese Encephalitis Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 56
Table 63: Japanese Encephalitis Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 57
Table 64: Japanese Encephalitis Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 57
Table 65: Meningococcal Meningitis Therapeutics Market, Global, Revenue ($m), 2002-2010 60
Table 66: Meningococcal Meningitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 60
Table 67: Meningococcal Meningitis Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 61
Table 68: Meningococcal Meningitis Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 61
Table 69: Meningococcal Meningitis Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 62
Table 70: Meningococcal Meningitis Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 62
Table 71: Travel Vaccines Therapeutics Market, Global Product Pipeline by Phase, 2011 66
Table 72: Travel Vaccines Therapeutics Market, Global Product Pipeline by Indication, 2011 67
Table 73: Hepatitis A Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 68
Table 74: Hepatitis A Therapeutics Market, Pipeline, Phase III Molecules, 2011 68
Table 75: Hepatitis B Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 69
Table 76: Hepatitis B Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 70
Table 77: Hepatitis B Therapeutics Market, Pipeline, Phase I Molecules, 2011 70
Table 78: Hepatitis B Therapeutics Market, Pipeline, Phase II Molecules, 2011 71
Table 79: Hepatitis B Therapeutics Market, Pipeline, Phase III Molecules, 2011 73
Table 80: Rabies Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 75
Table 81: Rabies Therapeutics Market, Pipeline, Phase I Molecules, 2011 75
Table 82: Rabies Therapeutics Market, Pipeline, Phase II Molecules, 2011 75
Table 83: Typhoid Fever Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 76
Table 84: Typhoid Fever Therapeutics Market, Pipeline, Phase I Molecules, 2011 76
Table 85: Typhoid Fever Therapeutics Market, Pipeline, Phase II Molecules, 2011 77
Table 86: Yellow Fever Therapeutics Market, Pipeline, Phase I Molecules, 2011 78
Table 87: Yellow Fever Therapeutics Market, Pipeline, Phase II Molecules, 2011 78
Table 88: Japanese Encephalitis Therapeutics Market, Pipeline, Phase II Molecules, 2011 79
Table 89: Japanese Encephalitis Therapeutics Market, Pipeline, Phase III Molecules, 2011 79
Table 90: Enterotoxigenic Escherichia Coli Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 80
Table 91: Enterotoxigenic Escherichia Coli Therapeutics Market, Pipeline, Phase I Molecules, 2011 80
Table 92: Meningococcal Meningitis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 81
Table 93: Meningococcal Meningitis Therapeutics Market, Pipeline, Phase II Molecules, 2011 82
Table 94: Meningococcal Meningitis Therapeutics Market, Pipeline, Phase III Molecules, 2011 83
Table 95: Travel Vaccines Therapeutics Market, Global, Major M&A Deals by Value ($m), 2004-2011 95
Table 96: Travel Vaccines Therapeutics Market, Global, Licensing Agreements by Value ($m), 2004-2011 100
1.2 List of Figures
Figure 1: Travel Vaccines Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 12
Figure 2: Travel Vaccines Therapeutics Market, Market Drivers and Barriers, 2010-2017 13
Figure 3: Travel Vaccines Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 15
Figure 4: Travel Vaccines Therapeutics Market, the US, Revenue Forecasts ($m), 2002-2017 17
Figure 5: Travel Vaccines Therapeutics Market, the US, Cost of Vaccination ($), 2002-2017 18
Figure 6: Travel Vaccines Therapeutics Market, the US, Vaccinated Travelers Forecasts (million), 2002-2017 19
Figure 7: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 20
Figure 8: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Cost of Vaccination ($), 2002-2017 21
Figure 9: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Vaccinated Travelers Forecasts (million), 2002-2017 22
Figure 10: Travel Vaccines Therapeutics Market, Japan, Revenue Forecasts ($m), 2002-2017 23
Figure 11: Travel Vaccines Therapeutics Market, Japan, Cost of Vaccination ($), 2002-2017 24
Figure 12: Travel Vaccines Therapeutics Market, Japan, Vaccinated Travelers Forecasts (million), 2002-2017 25
Figure 13: Travel Vaccines Therapeutics Market, Rest of the World, Revenue Forecasts, 2002-2017 26
Figure 14: Travel Vaccines Therapeutics Market, Rest of the World, Cost of Vaccination ($), 2002-2017 27
Figure 15: Travel Vaccines Therapeutics Market, Rest of the World, Vaccinated Travelers Forecasts (million), 2002-2017 28
Figure 16: Hepatitis A Therapeutics Market, Geographical Distribution of Hepatitis A 29
Figure 17: Hepatitis A Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 30
Figure 18: Hepatitis A Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 31
Figure 19: Hepatitis A Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 32
Figure 20: Hepatitis A Therapeutics Market, Market Drivers and Barriers, 2010-2017 33
Figure 21: Hepatitis B Therapeutics Market, Geographical Distribution of Hepatitis B 34
Figure 22: Hepatitis B Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 35
Figure 23: Hepatitis B Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 36
Figure 24: Hepatitis B Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 37
Figure 25: Hepatitis B Therapeutics Market, Market Drivers and Barriers, 2010-2017 38
Figure 26: Rabies Vaccine Therapeutics Market, Geographical Distribution of Rabies 39
Figure 27: Rabies Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 40
Figure 28: Rabies Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 41
Figure 29: Rabies Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 42
Figure 30: Rabies Therapeutics Market, Market Drivers and Barriers, 2010-2017 43
Figure 31: Typhoid Fever Therapeutics Market, Geographical Distribution of Typhoid Fever 44
Figure 32: Typhoid Fever Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 45
Figure 33: Typhoid Fever Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 46
Figure 34: Typhoid Fever Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 47
Figure 35: Typhoid Fever Therapeutics Market, Market Drivers and Barriers, 2010-2017 48
Figure 36: Yellow Fever Vaccine Therapeutics Market, Geographical Distribution of Yellow Fever 49
Figure 37: Yellow Fever Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 50
Figure 38: Yellow Fever Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 51
Figure 39: Yellow Fever Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 52
Figure 40: Yellow Fever Therapeutics Market, Market Drivers and Barriers, 2010-2017 53
Figure 41: Japanese Encephalitis Therapeutics Market, Geographical Distribution of Japanese Encephalitis 54
Figure 42: Japanese Encephalitis Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 55
Figure 43: Japanese Encephalitis Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 56
Figure 44: Japanese Encephalitis Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 57
Figure 45: Japanese Encephalitis Therapeutics Market, Market Drivers and Barriers, 2010-2017 58
Figure 46: Meningococcal Meningitis Therapeutics Market, Geographical Distribution of Meningococcal Meningitis 59
Figure 47: Meningococcal Meningitis Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 60
Figure 48: Meningococcal Meningitis Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 61
Figure 49: Meningococcal Meningitis Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 62
Figure 50: Meningococcal Meningitis Therapeutics Market, Market Drivers and Barriers, 2010-2017 63
Figure 51: Travel Vaccine Therapeutics Market, Global, Geographical Distribution of Enterotoxigenic Escherischia Coli 64
Figure 52: Enterotoxigenic Escherischia Coli Therapeutics Market, Market Drivers and Barriers, 2010-2017 65
Figure 53: Travel Vaccines Therapeutics Market, Global Product Pipeline by Phase (%), 2011 66
Figure 54: Travel Vaccines Therapeutics Market, Global Product Pipeline by Indication (%), 2011 67
Figure 55: Hepatitis A Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 68
Figure 56: Hepatitis B Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 69
Figure 57: Rabies Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 74
Figure 58: Typhoid Fever Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 76
Figure 59: Yellow Fever Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 78
Figure 60: Japanese Encephalitis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 79
Figure 61: Enterotoxigenic Escherichia Coli Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 80
Figure 62: Meningococcal Meningitis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 81
Figure 63: Travel Vaccines Therapeutics Market, Global, Market Share Analysis by Company (%), 2010 84
Figure 64: Travel Vaccines Therapeutics Market, Sanofi Pasteur, Company Overview, 2011 85
Figure 65: Travel Vaccines Therapeutics Market, Sanofi Pasteur, SWOT Analysis, 2011 86
Figure 66: Travel Vaccines Therapeutics Market, GSK, Company Overview, 2011 87
Figure 67: Travel Vaccines Therapeutics Market, GSK, SWOT Analysis, 2011 88
Figure 68: Travel Vaccines Therapeutics Market, Merck & Co., Inc, Company Overview, 2011 88
Figure 69: Travel Vaccines Therapeutics Market, Merck & Co., SWOT Analysis, 2011 89
Figure 70: Travel Vaccines Therapeutics Market, Novartis AG, Company Overview, 2011 90
Figure 71: Travel Vaccines Therapeutics Market, Novartis AG, SWOT Analysis, 2011 90
Figure 72: Travel Vaccines Therapeutics Market, Intercell AG, Company Overview, 2011 91
Figure 73: Travel Vaccines Therapeutics Market, Intercell AG, SWOT Analysis, 2011 91
Figure 74: Travel Vaccines Therapeutics Market, Global, M&A Deals by Year, 2004-2011 92
Figure 75: Travel Vaccines Therapeutics Market, Global, M&A Deals by Geography, 2004-2011 93
Figure 76: Travel Vaccines Therapeutics Market, Global, M&A Deals by Value ($m), 2004-2011 94
Figure 77: Travel Vaccines Therapeutics Market, Global, M&A Deals by Deal Type, 2004-2011 96
Figure 78: Travel Vaccines Therapeutics Market, Global, M&A Deals by Deal Sub-Type, 2004-2011 97
Figure 79: Travel Vaccines Therapeutics Market, Global, Licensing Agreements by Year, 2004-2011 98
Figure 80: Travel Vaccines Therapeutics Market, Global, Licensing Agreements by Geography, 2004-2011 99
Figure 81: Travel Vaccines Therapeutics Market, Global, Co-Developments by Year (%), 2004-2011 101
Figure 82: Travel Vaccines Therapeutics Market, Global, Co-Developments by Geography (%), 2004-2011 102
Companies mentioned
Sanofi Pasteur
GlaxoSmithKline plc
Merck & Co., Inc
Novartis AG
Intercell AG
To order this report:
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker